Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00288275
Recruitment Status : Terminated
First Posted : February 7, 2006
Last Update Posted : October 5, 2012
Information provided by (Responsible Party):
Precision Therapeutics

Brief Summary:
Chemoresponse assays (lab test) measure the effect that chemotherapy treatment has on a patient's cancer cells in the lab. This test has shown success in a retrospective study in predicting how an individual patient's tumor will respond to a given chemotherapy and how treatment utilizing an agent that the test said that a patient's cells would be sensitive too corresponds to a longer progression free interval. This study will determine the ability of two tests used to predict the success of chemotherapy in recurrent, persistent, or refractory cancer of the ovaries, fallopian tube(s) or peritoneum by measuring how long patients live without progression.

Condition or disease
Ovarian Cancer Fallopian Tube Cancer Peritoneal Neoplasms

Detailed Description:

The traditional treatment course for new cases of ovarian, fallopian tube, or peritoneal cancer is cytoreductive surgery followed by chemotherapy with paclitaxel in combination with carboplatin. Unfortunately, despite high initial response rates, the majority of patients recur and subsequent therapy is much less likely to be effective. The use of ineffective chemotherapy can result in unnecessary toxicity and costs, delay of more effective treatment, and the potential for the development of cross-resistance to additional drugs. The ability to individualize therapy by providing the treating physician with ex vivo response information on a panel of drugs should aid in the selection of effective therapy for individual patients, thus resulting in improved outcomes.

Resistance to chemotherapy cannot be predicted by either clinical or histological examination. Historically, the ex vivo sensitivity and resistance of tumor cells has been evaluated as a tool for predicting the clinical response of the patient to therapy. In this study, chemotherapy drugs will be tested using both the Precision Therapeutics' ChemoFx Assay and the Yale Apoptosis Assay. The assay results will be compared to clinical outcomes that will be reported at regular intervals. Blood, tumor pathology slides, and excess tumor cells (if available) will be used to characterize common polymorphisms in drug metabolizing enzymes as well as other molecular markers potentially associated with tumor response.

This is a one-arm validation trial with a goal of approximately 256 evaluable patients recruited from multiple sites. Patients will be drawn from the Yale -New Haven Medical Center and multiple additional sites as needed to meet accrual goals. The patients will be treated with FDA approved drugs and/or drug combinations based on the medical judgment of the treating physician. The study is not randomized and the results of the assay will not be used in the decision process for which agent to select for treatment, but are made available to the treating physician upon further progression.

Study Type : Observational
Estimated Enrollment : 256 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay With Progression-Free Survival in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer.
Study Start Date : July 2004
Actual Study Completion Date : October 2012

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 1. Every Treatment Cycle 2. Every 3 months for the first 2 years post treatment 3. Every 6 months for the next 3 years post treatment 4. Annually thereafter. ]

Secondary Outcome Measures :
  1. Tumor Response [ Time Frame: 1. Every treatment cycle 2. Every 3 months for the first 2 years post treatment 3. Every 6 months for the next 3 years post treatment 4. Annually thereafter. ]

Biospecimen Retention:   Samples With DNA
Leftover tumor cells from the test, pathology slides, and blood samples will be collected and stored to look for potential genetic variations related to drug pathway genes to identify patterns associated with clinical outcome.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Approximately 500 patients will be enrolled at 20-30 US sites. Patients have been diagnosed with persistent, refractory, or recurrent epithelial ovarian, peritoneal, or fallopian tube cancer.

Inclusion Criteria:

  • Patient has been diagnosed with persistent, refractory, or recurrent epithelial ovarian, peritoneal, or fallopian tube carcinoma.
  • Patient must have documented disease defined by physical exam, clinically significant increases in CA-125 (as defined by protocol), CT, MRI scan, PET, x-ray or ultrasound for whom cytoreduction, excisional biopsy, incisional biopsy, or paracentesis is medically indicated, or in the alternative, have agreed to a core biopsy of the primary site, a secondary metastatic site, or a paracentesis or thoracentesis for fluid collection.
  • Patient has disease of one of the following histologic epithelial cell types: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, transitional cell carcinoma, clear cell carcinoma, or adenocarcinoma, not otherwise specified (N.O.S.). Cytologic confirmation of diagnosis is acceptable for patients treated with neoadjuvant therapy who have not had a surgical procedure for a histologic confirmation.
  • Patient has only received one or two prior chemotherapy regimens for their ovarian, peritoneal, or fallopian tube carcinoma. Multiple previous regimens of Taxol/Carboplatin will be counted as 1 prior chemotherapy regimen (e.g., A patient who receives first line Taxol/Carboplatin, then recurs, then receives Taxol/Carboplatin will be considered to have had only 1 prior regimen.)
  • Patient must have completed prior chemotherapy regimens at least 3 weeks prior to tissue extraction.
  • Patient must have an estimated life expectancy of greater than six months, as determined by the investigator.
  • Patient requires chemotherapy and the investigator plans to administer one of the regimens of interest as deemed by her physician.
  • Patient must be a female and at least 18 years of age. Ovarian cancer is a disease that occurs only in women and is exceedingly rare in females under the age of 18.
  • Patient must have an ECOG Performance Status of 0, 1, or 2.
  • Tumor tissue or ascitic fluid must be available for the assays. Ascites or Pleural alone may be collected and submitted as the sample tissue, but the patient must also have measurable disease as demonstrated by a CA-125 level 2X ULN or measurable lesions on imaging to be eligible.
  • Patient must have signed an approved consent form.

Exclusion Criteria:

  • Patient has ovarian stromal, mixed mullerian, or germ cell tumors
  • Patient has borderline carcinoma (uncertain malignant potential)
  • Pregnant or lactating patients
  • Patients of childbearing potential not employing adequate contraception.
  • Patients who are at risk of failure of compliance to the visit schedules and procedures.
  • The investigator plans to use an assay to select the chemotherapy drug regimen. The investigator may submit the patient's tissue for testing with other assays, but may not use the results of those assays to select the chemotherapy regimen for the patient for this trial.
  • Patients with synchronous primary endometrial cancer or a past history of primary endometrial cancer are excluded unless all of the following conditions are met: Stage not greater than I-B, Less than 3mm invasion without vascular or lymphatic invasion, NO poorly differentiated subtype, including papillary serous, clear cell, or othe FIGO Grade 3 lesion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00288275

  Hide Study Locations
United States, California
University of California
Irvine, California, United States, 92868
Kaiser Permanente
Los Angeles, California, United States, 90027
United States, Connecticut
Yale University Medical Center
New Haven, Connecticut, United States, 06520
United States, Florida
Florida Gynecologic Oncology
Fort Myers, Florida, United States, 33901
St. Vincents Medical Center
Jacksonville, Florida, United States, 32204
The Florida Hospital
Orlando, Florida, United States, 32804
Women's Cancer Associates
St. Petersburg, Florida, United States, 33701
United States, Georgia
Atlanta Medical Center
Atlanta, Georgia, United States, 30312
Southeastern Gynecologic Oncology Riverdale
Riverdale, Georgia, United States, 30274
United States, Illinois
Northwestern University/Prentice Women's Hospital
Chicago, Illinois, United States, 60611
Rush University
Chicago, Illinois, United States, 60612
United States, Indiana
St. Vincent Indianapolis Hospital
Indianapolis, Indiana, United States, 46260
United States, Kentucky
St. Elizabeth Medical Center
Edgewood, Kentucky, United States, 41017
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University
St. Louis, Missouri, United States, 63110
Saint Louis University
St. Louis, Missouri, United States, 63117
United States, New Jersey
The Cooper Health System
Camden, New Jersey, United States, 08103
Saint Barnabas Medical Center
West Orange, New Jersey, United States, 07052
United States, New York
Schwartz Gynecologic Oncology, PLLC
Brightwaters, New York, United States, 11718
United States, Ohio
University of Cincinnati Medical Center Barrett Cancer Center
Cincinnati, Ohio, United States, 45219
University Hospital Case Medical Center
Cleveland, Ohio, United States, 44106
Cleveland Clinic
Cleveland, Ohio, United States, 44195
University of Toledo Medical Center
Toledo, Ohio, United States, 43614
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73190
United States, Oregon
Legacy Health System
Portland, Oregon, United States, 97227
United States, Pennsylvania
Abington Memorial Hospital
Abington, Pennsylvania, United States, 19001
UPMC Cancer Center at Magee Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
Lankenau Hospital, Mainline Health System
Wynnwood, Pennsylvania, United States, 19096
United States, Rhode Island
Women & Infants Hospital
Providence, Rhode Island, United States, 02905-2499
United States, South Carolina
Cancer Centers of the Carolinas
Greenville, South Carolina, United States, 29605
United States, Tennessee
ACORN - The West Clinic
Memphis, Tennessee, United States, 38138
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
The Methodist Hospital
Houston, Texas, United States, 77030
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
United States, Wisconsin
University of Wisconsin, Madison
Madison, Wisconsin, United States, 53715
Sponsors and Collaborators
Precision Therapeutics
Principal Investigator: Thomas J Rutherford, MD Yale University
Study Director: Hong Ma, MD Precision Therapeutics, Inc.

Responsible Party: Precision Therapeutics Identifier: NCT00288275     History of Changes
Obsolete Identifiers: NCT00301717
Other Study ID Numbers: PT-301
First Posted: February 7, 2006    Key Record Dates
Last Update Posted: October 5, 2012
Last Verified: October 2012

Keywords provided by Precision Therapeutics:
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Precision Therapeutics

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases